SEC Form 4 · accession 0001209191-17-053528
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kalevi Kurkijarvi
Director
Period of report
Aug 17, 2017
Accepted (ET)
Sep 20, 2017 · 7:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 17, 2017 | S | 2,000 | $40.74 | D | 30,000 | D | |
| Common Stock | Sep 18, 2017 | S | 2,000 | $52.55 | D | 28,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 Plan.
- F2The shares were sold at prices ranging from $40.70 to $40.7501. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.